MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which combines semaglutide with dual amylin and calcitonin receptor agonist ...

GLP-1 receptor agonists are peptide-based drugs used for managing diabetes and for weight loss, but these treatments have had shortages recently. Now, through a process called in vivo antibody ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The market is evolving from GLP-1s to GLP-1/GIPs, to so-called triple Gs (GLP1/GIP/glucagon) like Eli Lilly’s tirzepatide, amylin analogs, GLP-1/amylin analogs, GLP1/GIP-amylin analogs ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

Zealand and Roche will co-develop and co-commercialise Zealand’s amylin analogue petrelintide as a monotherapy, and in combination therapies. The first planned combination will pair petrelintide with ...

“It is our view that among investigated dual-acting agents (GLP-1/GIP, GLP-1/glucagon, GLP-1/amylin), the combination pursued by Eli Lilly’s Zepbound, Amgen’s MariTide, Viking’s VK2735 and ...

CagriSema consists of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). The combination works by decreasing hunger and increasing ...